PIERCE2 as A Drug Target for Inflammatory Neurodegenerative Diseases

Target Name: PIERCE2

NCBI ID: G145788

PIERCE2

PIERCE2 as A Drug Target for Inflammatory Neurodegenerative Diseases

PIERCE2 (PIRC2_HUMAN) as a Drug Target and Biomarker: Implications for the Treatment of Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and progressive motor neuron disease, are characterized by the progressive damage of the central nervous system (CNS) and peripheral nerves due to the inflammatory response of the immune system. These conditions often result in significant morbidity and mortality, making them a significant public health burden. The identification of potential drug targets and biomarkers for the treatment of these diseases is crucial for the development of new therapeutic approaches. One of the promising targets is the protein PIERCE2 (PIRC2_HUMAN), which has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

PIERCE2 (Proteolytic Inhibitor of Enhanced Neurodegeneration-2) is a protein that is expressed in various tissues, including brain, spinal cord, and peripheral nerves, and has been shown to play a critical role in the regulation of neurodegeneration. The protein is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain contains a putative transmembrane anchoring region and is involved in the regulation of cell adhesion and signaling, while the C-terminal cytoplasmic domain is involved in protein-protein interactions and may be involved in the regulation of cellular processes such as autophagy and apoptosis.

Recent studies have demonstrated that PIERCE2 is involved in the regulation of neurodegeneration by suppressing the pro-inflammatory response of immune cells. Specifically, studies have shown that PIERCE2 can inhibit the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IFN-纬, by suppressing the activity of the transcription factor NF-kappa-B. Additionally, PIERCE2 has been shown to modulate the expression of genes involved in cell survival and proliferation, including the genes encoding the anti-inflammatory protein PDGF-BB and the cell cycle regulator p21.

These findings suggest that PIERCE2 may be a potential drug target for the treatment of inflammatory neurodegenerative diseases. By inhibiting the pro-inflammatory response and modulating cellular processes involved in neurodegeneration, PIERCE2 may have therapeutic benefits for conditions such as multiple sclerosis, rheumatoid arthritis, and progressive motor neuron disease.

Another potential mechanism by which PIERCE2 may be involved in the treatment of inflammatory neurodegenerative diseases is its role in the regulation of the immune response. Chronic inflammation can contribute to the development and progression of inflammatory neurodegenerative diseases, and PIERCE2 has been shown to play a role in modulating the immune response. Studies have shown that PIERCE2 can inhibit the recruitment of immune cells to the site of neurodegeneration, and that this effect is dependent on the expression level of the protein.

Furthermore, PIERCE2 has been shown to have neuroprotective effects in various models of neurodegeneration, such as the mouse model of neurofibrosis. In these models, PIERCE2 has been shown to protect against neurotoxicity and glial cell death, as well as the loss of behavioral and cognitive functions.

In conclusion, PIERCE2 is a protein that has been identified as a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its involvement in the regulation of the immune response and its neuroprotective effects make it a promising target for small molecule inhibitors. Further research is needed to understand the full implications of PIERCE2 as a drug target and biomarker

Protein Name: Piercer Of Microtubule Wall 2

Functions: Microtubule inner protein involved in the attachment of outer dynein arms (ODAs) to dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "PIERCE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIERCE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets